Filing Flows › China Pharma Holdings (CPHI) › R&D spending
China Pharma Holdings (CPHI) R&D spending by quarter
China Pharma Holdings' R&D spending was $19K in Q2 2026 (second quarter 2026), -77% from Q1 2026. Over the last 6 quarters it ranged from $1K (Q4 2024) to $84K (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $19K | -77% | -9% |
| Q1 2026 | $84K | +108% | +183% |
| Q3 2025 | $40K | +92% | — |
| Q2 2025 | $21K | -29% | — |
| Q1 2025 | $30K | 54× | — |
| Q4 2024 | $1K | — | — |
Q2 2026 at a glance
China Pharma Holdings, Q2 2026: revenue $948K (-8% year over year), operating margin -151.0%, net loss $1.5M, operating cash flow −$33K. The chart follows the revenue to costs, profit and cash.
Questions
What is China Pharma Holdings' R&D spending?
China Pharma Holdings' R&D spending was $19K in Q2 2026 (second quarter 2026), -77% from Q1 2026.
How has China Pharma Holdings' R&D spending changed?
Over the last 6 quarters it ranged from $1K (Q4 2024) to $84K (Q1 2026).